Aurobindo Pharma CB uses rare premium structure

Strong expansion story allows company to fix conversion price on 25% of the deal in 12 months time; investors compensated by high yield and high bond floor.
One of India's top-five pharmaceutical companies, Aurobindo Pharma last Friday April 21 sold a two-tranche, zero-coupon, five-year convertible bond to raise $200 million, which it intends to use primarily for overseas investments and acquisitions.

The bonds saw the Indian issuer opt for a typically high conversion premium on the larger of the two tranches, while the smaller tranche upped the stakes for investors somewhat as the conversion price wonÆt be fixed for another year.

Because of the greater certainty, investors were more interested in the larger Tranche A which ended up with a final size of $150 million, after joint bookrunners Barclays Capital and Deutsche Bank tested the market with a size range of $100...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222